The classification of multiple sclerosis (MS) has been established by Lublin in 1996 and
revised in 2013. The revision includes clinically isolated syndrome, relapsing-remitting …

A major therapeutic goal in the treatment of multiple sclerosis (MS) is to prevent the
accumulation of disability over an often decades-long disease course. Disability progression …

Aging is associated with a progressive decline of innate and adaptive immune responses,
called immunosenescence. This phenomenon links to different multiple sclerosis (MS) …

Background: The Oxford Big Data Institute, multiple sclerosis (MS) physicians and Novartis
aim to address unresolved questions in MS with a novel comprehensive clinical trial data …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …

Background and Objectives The specificity of novel blood biomarkers for multiple sclerosis
(MS)–related neurodegeneration is unclear because neurodegeneration also occurs during …

The available clinical evidence examining DMT discontinuation in older people with MS
remains inconclusive. More robust evidence from clinical trials and real-world data will be …

Objectives The rapid expansion in treatment options for relapsing-remitting multiple
sclerosis (RRMS) of the past decade requires clinical decision making on the sequential …

Background: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the
central nervous system. Pediatric-onset MS (POMS), defined as onset of MS before 18 years …

Objectives Most patients with multiple sclerosis (MS) switch between disease-modifying
therapies (DMTs) during their lifetime. Our aim was to develop an MS cost-utility model that …